 Hello Immunization Partners,
Please share the following information with staff and colleagues.
On December 12, 2024, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (MMWR) entitledUse of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024.
On October 2024, ACIP recommended that all persons aged 65 years and older and persons aged 6 months through 64 years with moderate or severe immunocompromise receive a second 2024–2025 COVID-19 vaccine dose 6 months after their last dose. Further, ACIP recommended that persons aged 6 months and older with moderate or severe immunocompromise may receive additional doses based on shared clinical decision-making.
Specifically, on October 23, 2024, ACIP recommended that all persons aged 65 years and older receive a second dose of 2024–2025 COVID-19 vaccine (Table) 6 months (minimum interval = 2 months) after the last dose of 2024–2025 COVID-19 vaccine. If an adult is 65 years and older, is previously unvaccinated and receiving Novavax, 2 doses are recommended as an initial vaccination series and should be followed by a third dose of any age-appropriate 2024–2025 COVID-19 vaccine 6 months (minimum interval = 2 months) after the second dose.
Also on October 23, 2024, ACIP recommended that persons aged 6 months through 64 years with moderate or severe immunocompromise receive a second dose of 2024–2025 COVID-19 vaccine 6 months after the last 2024–2025 COVID-19 vaccine dose (minimum interval = 2 months). For all persons with moderate or severe immunocompromise, 2 or more doses of 2024–2025 COVID-19 vaccine are recommended; 1 of the 2 recommended 2024–2025 COVID-19 vaccine doses may be a part of the initial vaccination series, and in this case, the remaining dose is recommended 6 months (minimum interval = 2 months) after completion of the initial vaccination series.
ACIP also recommended that persons aged 6 months and older with moderate or severe immunocompromise may receive additional 2024–2025 COVID-19 vaccine doses (i.e., a total of 3 or more doses of 2024–2025 COVID-19 vaccine) based on shared clinical decision-making, which should be guided by the clinical judgment of a health care provider and personal preference and circumstances of the patient.
Additional clinical considerations, including detailed schedules and tables by age and vaccination history for persons with and without moderate or severe immunocompromise, are available at: CDC Interim Clinical Considerations: Use of COVID-19 Vaccines in the United States.
Thank you for all you do!
Oakland County Health & Human Services, Immunization Action Plan
|
